Adagene's Muzastotug Shows Promise in Late-Stage Colorectal Cancer
Event summary
- Adagene's Phase 1b/2 study of muzastotug in combination with pembrolizumab (KEYTRUDA®) demonstrated a 31% overall response rate (ORR) in the 20 mg/kg dose cohort, compared to 13% in the 10 mg/kg cohort.
- The 20 mg/kg cohort showed a median duration of response (mDOR) that was not yet reached, while the 10 mg/kg cohort had a mDOR of 6.2 months.
- Median progression-free survival (PFS) was 6.7 months in the 20 mg/kg cohort versus 4.8 months in the 10 mg/kg cohort.
- A randomized Phase 2 trial is currently enrolling patients, with results expected in 1H 2027, and a potential registration trial is planned following dose regimen establishment.
The big picture
MSS colorectal cancer represents a significant unmet medical need, with limited treatment options and poor outcomes. Adagene's approach of masking CTLA-4 antibodies to improve safety and efficacy addresses a key challenge in immunotherapy, potentially expanding the therapeutic window for this patient population. The Fast Track designation underscores the FDA's recognition of the potential benefit, but successful Phase 2 results are essential to realize this opportunity.
What we're watching
- Clinical Efficacy
- The success of the ongoing Phase 2 trial will be critical in validating the observed dose-dependent efficacy and establishing a clear path to registration, particularly given the differing results between the Q3W and Q6W regimens.
- Regulatory Pathway
- Adagene's ability to secure FDA feedback on the optimal dose regimen and navigate the registration process will heavily influence the program's timeline and commercial potential.
- Competitive Landscape
- The emergence of new therapies for MSS colorectal cancer will likely intensify competition, requiring Adagene to demonstrate a clear clinical and safety advantage for muzastotug.
Related topics